

AroCell Q4 - Nearing positive operating cash flow

Redeye leaves its estimates and valuation untouched following the report. However, our gross margin assumptions might be reconsidered (downward) if the coming quarters do not show better gross margin development.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

AroCell Q4 - Nearing positive operating cash flow